• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    QuidelOrtho Reports First Quarter 2025 Financial Results

    5/7/25 4:05:00 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $QDEL alert in real time by email

    ― Total revenue of $693 million, growth of 5% as reported and 6% in constant currency, excluding COVID-19 and Donor Screening ―

    ― Strong execution on cost-savings initiatives driving improved margins and profitability ―

    ― Company maintains full-year 2025 financial guidance ―

    First Quarter 2025 Results

    (all comparisons are to the prior year period)

    • Total revenue was $693 million, as reported
      • Non-respiratory revenue was $573 million, which was flat to the prior year period as reported and an increase of 2% in constant currency
        • Labs revenue grew 5% as reported and 7% in constant currency
        • Donor Screening revenue declined by 62% as the Company continues to wind down the U.S. portion of that business
      • Respiratory revenue was $120 million; excluding COVID-19, respiratory revenue grew 11% as reported and in constant currency
    • GAAP operating expenses1 of $240 million decreased by $24 million or 9%; non-GAAP operating expenses of $233 million decreased by $18 million or 7%, both driven by the Company's cost-saving initiatives
    • GAAP operating margin increased from (247%) to 5%; adjusted EBITDA margin was 23%, an increase of 450 basis points

    QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs, and transfusion medicine, today announced financial results for the first quarter ended March 30, 2025.

    "We delivered solid first quarter performance driven by growth in our Labs business and the strength of our recurring revenue business model," said Brian J. Blaser, President and Chief Executive Officer, QuidelOrtho. "Our ongoing operational improvement initiatives contributed meaningfully to our results. We are proactively addressing macroenvironment operating challenges and maintaining our full-year 2025 financial guidance based on our current business outlook. As we look ahead, we remain committed to commercial excellence, margin expansion, and supporting our customers and the patients who rely on our products."

    First Quarter 2025

    The Company reported total revenue for the first quarter of 2025 of $693 million, compared to $711 million in the prior year period. The decrease in total revenue was primarily due to lower COVID-19 and Donor Screening revenue compared to the prior year period. Foreign currency translation had an unfavorable impact of 150 basis points on the Company's first quarter 2025 revenue.

    GAAP diluted loss per share for the first quarter of 2025 was $0.19, compared to diluted loss per share of $25.50 in the prior year period. GAAP net loss for the first quarter of 2025 was $13 million, compared to $1.71 billion in the prior year period, which included a non-cash goodwill impairment charge of $1.74 billion. GAAP operating income for the first quarter of 2025 was $33 million, compared to an operating loss of $1.76 billion in the prior year period, and GAAP operating margin was 5%, compared to (247%) in the prior year period. First quarter 2025 results included $16 million in integration-related charges.

    Adjusted diluted earnings per share ("EPS") for the first quarter of 2025 was $0.74, compared to $0.44 in the prior year period. Adjusted EBITDA for the first quarter of 2025 was $160 million, compared to $132 million in the prior year period. Adjusted EBITDA margin for the first quarter of 2025 was 23%, compared to 19% in the prior year period. The year-over-year increase was driven by the Company's cost-savings initiatives.

    1 Operating expenses is comprised of Selling, marketing and administrative and Research and development expenses.

    Full-year 2025 Financial Guidance

    Based on its current business outlook, the Company is maintaining its fiscal 2025 financial guidance provided on February 12, 2025, as follows:

    Total revenues (reported)

    $2.60 - $2.81 billion*

    Adjusted EBITDA

    $575 – $615 million

    Adjusted EBITDA margin

    22%

    Adjusted diluted EPS

    $2.07 - $2.57

    * Full-year 2025 total reported revenue is expected to be negatively impacted by foreign currency exchange of $29 million based on currency rates as of April 27, 2025. Please see page 6 of the First Quarter 2025 Financial Results presentation on the "Investor Relations" page of the Company's website for the full list of assumptions on which the Company's 2025 financial guidance is based.

    A reconciliation of forward-looking non-GAAP measures, including adjusted EBITDA, adjusted EBITDA margin and adjusted diluted EPS, to the most directly comparable GAAP measures is not provided because comparable GAAP measures for such measures are not reasonably accessible or reliable due to the inherent difficulty in forecasting and quantifying measures that would be necessary for such reconciliation. We are not, without unreasonable effort, able to reliably predict the impact of impairment charges and related tax benefits, employee compensation costs and other adjustments. These items are uncertain, depend on various factors and may have a material impact on our future GAAP results. In addition, the Company believes any such reconciliation would imply a degree of precision and certainty that could be confusing to investors. See "Forward-Looking Statements" and "Non-GAAP Financial Measures."

    Conference Call Information

    QuidelOrtho will hold a conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results. Interested parties can access the call on the "Events & Presentations" section of the "Investor Relations" page of the Company's website at https://ir.quidelortho.com. Presentation materials will also be posted to the "Events & Presentations" section of the Investor Relations page of the Company's website at the time of the call. Those unable to access the webcast may join the call via phone by dialing 833-470-1428 (domestic) or +1 929-526-1599 (international) and entering Conference ID number 170283.

    A replay of the conference call will be available shortly after the event on the "Investor Relations" page of the Company's website under the "Events & Presentations" section.

    QuidelOrtho is dedicated to advancing diagnostics to power a healthier future. For more information, please visit quidelortho.com and follow QuidelOrtho on LinkedIn, Facebook and X.

    About QuidelOrtho Corporation

    QuidelOrtho Corporation (NASDAQ:QDEL) is a world leader in in-vitro diagnostics, developing and manufacturing intelligent solutions that transform data into understanding and action for more people in more places every day.

    Offering industry-leading expertise in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, bringing fast, accurate and reliable diagnostics when and where they are needed – from home to hospital, lab to clinic. So that patients, clinicians and health officials can spot trends sooner, respond quicker and chart the course ahead with accuracy and confidence.

    Building upon its many years of groundbreaking innovation, QuidelOrtho continues to partner with customers across the healthcare continuum and around the globe to forge a new diagnostic frontier. One where insights and solutions know no bounds, expertise seamlessly connects and a more informed path is illuminated for each of us.

    Source: QuidelOrtho Corporation

    Forward-Looking Statements

    This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are any statement contained herein that is not strictly historical, including, but not limited to, QuidelOrtho's commercial, integration and other strategic goals, financial guidance and related assumptions and other future financial condition and operating results, including expected results of operations or financial position, cost-savings and operational improvement initiatives, and other future plans, objectives, strategies, expectations and intentions. Without limiting the foregoing, the words "may," "will," "could," "would," "should," "might," "expect," "anticipate," "believe," "estimate," "plan," "intend," "goal," "project," "strategy," "future," "continue," "aim," "strive," "seek," or similar words, expressions or the negative of such terms or other comparable terminology are intended to identify forward-looking statements. Such statements are based on the beliefs and expectations of QuidelOrtho's management as of the date of this press release and are subject to significant known and unknown risks and uncertainties. Actual results or outcomes may differ significantly from those set forth or implied in the forward-looking statements. The following factors, among others, could cause actual results or outcomes to differ from those set forth or implied in the forward-looking statements: fluctuations in demand for QuidelOrtho's non-respiratory and respiratory products; supply chain, production, logistics, distribution and labor disruptions and challenges; the challenges and costs of integrating, restructuring and achieving anticipated synergies as a result of the business combination of Quidel Corporation and Ortho Clinical Diagnostics Holdings plc; and other macroeconomic, geopolitical, market, business, competitive and/or regulatory factors affecting the business of QuidelOrtho generally, including those arising from the effects of announced or future or amended tariffs, trade policies and global trade relations, as well as others discussed in QuidelOrtho's Annual Report on Form 10-K for the fiscal year ended December 29, 2024 and subsequent reports filed with the Securities and Exchange Commission (the "Commission"), including under Part I, Item 1A, "Risk Factors" of the Form 10-K. You should not rely on forward-looking statements as predictions of future events because these statements are based on assumptions that may not come true and are speculative by their nature. All forward-looking statements are based on information currently available to QuidelOrtho and speak only as of the date of this press release. QuidelOrtho undertakes no obligation to update any of the forward-looking information or time-sensitive information included in this press release, whether as a result of new information, future events, changed expectations or otherwise, except as required by law.

    Non-GAAP Financial Measures

    This press release contains financial measures that are considered non-GAAP financial measures under applicable rules and regulations of the Commission, including but not limited to "constant currency revenue changes, excluding COVID-19 and Donor Screening revenues," "constant currency Labs revenue changes," "constant currency respiratory revenue changes, excluding COVID-19 revenue," "non-GAAP operating expenses," "adjusted diluted EPS," "adjusted EBITDA," "adjusted EBITDA margin," and other non-GAAP financial measures included in the reconciliation tables accompanying this press release. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). These non-GAAP financial measures eliminate impacts of certain non-cash, unusual or other items that the Company does not consider indicative of its ongoing operating performance, and the Company generally uses these non-GAAP financial measures to facilitate management's financial and operational decision-making, including evaluation of the Company's historical operating results and comparison to competitors' operating results. The Company's definitions of these non-GAAP measures may differ from similarly titled measures used by others. These non-GAAP financial measures reflect an additional way of viewing aspects of the Company's operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of factors and trends affecting the Company's business. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company's reported results of operations, management strongly encourages investors to review the Company's consolidated financial statements and reports filed with the Commission in their entirety. Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the tables accompanying this press release.

     

    QuidelOrtho

    Consolidated Statements of Operations

    (Unaudited)

    (In millions except per share data)

     

     

    Three Months Ended

     

    March 30, 2025

     

    March 31, 2024

    Total revenues

    $

    692.8

     

     

    $

    711.0

     

    Cost of sales, excluding amortization of intangibles

     

    349.5

     

     

     

    378.9

     

    Selling, marketing and administrative

     

    187.0

     

     

     

    204.7

     

    Research and development

     

    53.2

     

     

     

    59.2

     

    Amortization of intangible assets

     

    48.0

     

     

     

    51.7

     

    Integration related costs

     

    16.1

     

     

     

    22.6

     

    Goodwill impairment charge

     

    —

     

     

     

    1,743.9

     

    Other operating expenses

     

    6.4

     

     

     

    8.0

     

    Operating income (loss)

     

    32.6

     

     

     

    (1,758.0

    )

    Interest expense, net

     

    40.0

     

     

     

    39.0

     

    Other expense, net

     

    1.4

     

     

     

    1.9

     

    Loss before income taxes

     

    (8.8

    )

     

     

    (1,798.9

    )

    Provision for (benefit from) income taxes

     

    3.9

     

     

     

    (92.9

    )

    Net loss

    $

    (12.7

    )

     

    $

    (1,706.0

    )

    Basic loss per share

    $

    (0.19

    )

     

    $

    (25.50

    )

    Diluted loss per share

    $

    (0.19

    )

     

    $

    (25.50

    )

    Weighted-average shares outstanding - basic

     

    67.5

     

     

     

    66.9

     

    Weighted-average shares outstanding - diluted

     

    67.5

     

     

     

    66.9

     

     

    QuidelOrtho

    Condensed Consolidated Balance Sheets

    (Unaudited)

    (In millions)

     

     

    March 30, 2025

     

    December 29, 2024

    ASSETS

     

     

     

    Current assets:

     

     

     

    Cash and cash equivalents

    $

    127.1

     

    $

    98.3

    Accounts receivable, net

     

    286.0

     

     

    282.4

    Inventories

     

    563.2

     

     

    533.7

    Prepaid expenses and other current assets

     

    239.8

     

     

    262.4

    Assets held for sale

     

    42.1

     

     

    42.1

    Total current assets

     

    1,258.2

     

     

    1,218.9

    Property, plant and equipment, net

     

    1,399.4

     

     

    1,380.2

    Right-of-use assets

     

    165.0

     

     

    168.7

    Goodwill

     

    670.9

     

     

    649.5

    Intangible assets, net

     

    2,697.9

     

     

    2,735.6

    Other assets

     

    270.2

     

     

    270.7

    Total assets

    $

    6,461.6

     

    $

    6,423.6

    LIABILITIES AND STOCKHOLDERS' EQUITY

     

     

     

    Current liabilities:

     

     

     

    Accounts payable

    $

    230.9

     

    $

    246.0

    Accrued payroll and related expenses

     

    135.3

     

     

    116.9

    Income tax payable

     

    5.8

     

     

    5.4

    Current portion of borrowings

     

    393.8

     

     

    341.8

    Other current liabilities

     

    281.4

     

     

    288.7

    Total current liabilities

     

    1,047.2

     

     

    998.8

    Operating lease liabilities

     

    163.3

     

     

    167.2

    Long-term borrowings

     

    2,105.9

     

     

    2,141.3

    Deferred tax liabilities

     

    78.2

     

     

    76.5

    Other liabilities

     

    69.8

     

     

    55.3

    Total liabilities

     

    3,464.4

     

     

    3,439.1

    Total stockholders' equity

     

    2,997.2

     

     

    2,984.5

    Total liabilities and stockholders' equity

    $

    6,461.6

     

    $

    6,423.6

     

    QuidelOrtho

    Condensed Consolidated Statements of Cash Flows

    (Unaudited)

    (In millions)

     

     

    Three Months Ended

     

    March 30, 2025

     

    March 31, 2024

    Cash provided by (used for) operating activities

    $

    65.6

     

     

    $

    (0.7

    )

    Cash used for investing activities

     

    (56.2

    )

     

     

    (20.2

    )

    Cash provided by (used for) financing activities

     

    17.6

     

     

     

    (18.5

    )

    Effect of exchange rates on cash

     

    1.7

     

     

     

    (1.1

    )

    Net increase (decrease) in cash, cash equivalents and restricted cash

     

    28.7

     

     

     

    (40.5

    )

    Cash, cash equivalents and restricted cash at beginning of period

     

    98.5

     

     

     

    119.5

     

    Cash, cash equivalents and restricted cash at end of period

    $

    127.2

     

     

    $

    79.0

     

     

     

     

     

    Reconciliation to amounts within the consolidated balance sheets:

     

     

     

    Cash and cash equivalents

    $

    127.1

     

     

    $

    78.5

     

    Restricted cash in Other assets

     

    0.1

     

     

     

    0.5

     

    Cash, cash equivalents and restricted cash

    $

    127.2

     

     

    $

    79.0

     

     

    QuidelOrtho

    Reconciliation of Non-GAAP Financial Information - Adjusted Net Income

    (In millions, except per share data; unaudited)

     

     

    Three Months Ended

     

    March 30, 2025

     

    Diluted EPS

     

    March 31, 2024

     

    Diluted EPS

    Net loss

    $

    (12.7

    )

     

    $

    (0.19

    )

     

    $

    (1,706.0

    )

     

    $

    (25.50

    )

    Adjustments:

     

     

     

     

     

     

     

    Amortization of intangibles

     

    48.0

     

     

     

     

     

    51.7

     

     

     

    Integration related costs

     

    16.1

     

     

     

     

     

    22.6

     

     

     

    Goodwill impairment charge

     

    —

     

     

     

     

     

    1,743.9

     

     

     

    Incremental depreciation on PP&E fair value adjustment

     

    5.2

     

     

     

     

     

    9.1

     

     

     

    Amortization of deferred cloud computing implementation costs

     

    4.3

     

     

     

     

     

    2.9

     

     

     

    EU medical device regulation transition costs

     

    0.2

     

     

     

     

     

    0.6

     

     

     

    Employee compensation charges

     

    —

     

     

     

     

     

    5.6

     

     

     

    Other adjustments

     

    0.9

     

     

     

     

     

    1.4

     

     

     

    Income tax impact of adjustments

     

    (10.2

    )

     

     

     

     

    (101.4

    )

     

     

    Discrete tax items

     

    (1.6

    )

     

     

     

     

    (0.6

    )

     

     

    Adjusted net income

    $

    50.2

     

     

    $

    0.74

     

     

    $

    29.8

     

     

    $

    0.44

     

    Weighted-average shares outstanding - diluted

     

     

     

    67.9

     

     

     

     

     

    67.3

     

     

    QuidelOrtho

    Reconciliation of Non-GAAP Financial Information - Non-GAAP Operating Expenses

    (In millions, unaudited)

     

     

    Three Months Ended March 30, 2025

     

    Three Months Ended March 31, 2024

     

    GAAP

     

    Adjustments(a)

     

    Non-GAAP

     

    GAAP

     

    Adjustments(a)

     

    Non-GAAP

    Selling, marketing and administrative

    $

    187.0

     

    $

    (6.8)

     

    $

    180.2

     

    $

    204.7

     

    $

    (12.3)

     

    $

    192.4

    Research and development

     

    53.2

     

     

    (0.5)

     

     

    52.7

     

     

    59.2

     

     

    (0.8)

     

     

    58.4

    Operating expenses

    $

    240.2

     

    $

    (7.3)

     

    $

    232.9

     

    $

    263.9

     

    $

    (13.1)

     

    $

    250.8

    (a)

    Includes the following non-GAAP adjustments: amortization of deferred cloud computing implementation costs, incremental depreciation on PP&E fair value adjustment, employee compensation charges, EU medical device regulation transition costs and other adjustments.

     

    QuidelOrtho

    Reconciliation of Non-GAAP Financial Information - Adjusted EBITDA

    (In millions, unaudited)

     

     

    Three Months Ended

     

    March 30, 2025

     

    March 31, 2024

    Net loss

    $

    (12.7

    )

     

    $

    (1,706.0

    )

    Depreciation and amortization

     

    107.1

     

     

     

    114.9

     

    Interest expense, net

     

    40.0

     

     

     

    39.0

     

    Provision for (benefit from) income taxes

     

    3.9

     

     

     

    (92.9

    )

    Integration related costs

     

    16.1

     

     

     

    22.6

     

    Goodwill impairment charge

     

    —

     

     

     

    1,743.9

     

    Amortization of deferred cloud computing implementation costs

     

    4.3

     

     

     

    2.9

     

    EU medical device regulation transition costs

     

    0.2

     

     

     

    0.6

     

    Employee compensation charges

     

    —

     

     

     

    5.6

     

    Other adjustments

     

    0.9

     

     

     

    1.4

     

    Adjusted EBITDA

    $

    159.8

     

     

    $

    132.0

     

     

     

     

     

    Total revenues

    $

    692.8

     

     

    $

    711.0

     

    Adjusted EBITDA margin

     

    23.1

    %

     

     

    18.6

    %

     

    QuidelOrtho

    Reconciliation of Non-GAAP Financial Information - Revenues by Business Unit and Region

    (In millions, unaudited)

     

     

    Three Months Ended

     

     

     

     

     

     

     

     

     

     

     

    March 30, 2025

     

    March 31, 2024

     

    % Change

     

    Currency

    Impact

     

    Constant

    Currency (a)

     

    Less: COVID-19

    revenue impact

     

    Constant Currency (a)

    ex COVID-19 Revenue

    Respiratory revenues

    $

    119.8

     

    $

    137.3

     

    (12.7)%

     

    (0.1)%

     

    (12.6)%

     

    (23.4)%

     

    10.8 %

    Non-Respiratory revenues

     

    573.0

     

     

    573.7

     

    (0.1)%

     

    (1.8)%

     

    1.7 %

     

    — %

     

    1.7 %

    Total revenues

    $

    692.8

     

    $

    711.0

     

    (2.6)%

     

    (1.5)%

     

    (1.1)%

     

    (4.0)%

     

    2.9 %

     

    Three Months Ended

     

     

     

     

     

     

     

     

     

     

     

    March 30, 2025

     

    March 31, 2024

     

    % Change

     

    Currency

    Impact

     

    Constant

    Currency (a)

     

    Less: COVID-19

    revenue impact

     

    Constant Currency (a)

    ex COVID-19 Revenue

    Labs

    $

    373.1

     

    $

    356.9

     

    4.5 %

     

    (2.2)%

     

    6.7 %

     

    (0.1)%

     

    6.8 %

    Immunohematology

     

    128.5

     

     

    127.0

     

    1.2 %

     

    (2.5)%

     

    3.7 %

     

    — %

     

    3.7 %

    Donor Screening

     

    12.8

     

     

    33.3

     

    (61.6)%

     

    (0.1)%

     

    (61.5)%

     

    — %

     

    (61.5)%

    Point of Care

     

    170.8

     

     

    186.6

     

    (8.5)%

     

    (0.1)%

     

    (8.4)%

     

    (15.9)%

     

    7.5 %

    Molecular Diagnostics

     

    7.6

     

     

    7.2

     

    5.6 %

     

    (1.6)%

     

    7.2 %

     

    (3.6)%

     

    10.8 %

    Total revenues

    $

    692.8

     

    $

    711.0

     

    (2.6)%

     

    (1.5)%

     

    (1.1)%

     

    (4.0)%

     

    2.9 %

     

    Three Months Ended

     

     

     

     

     

     

     

     

     

     

     

    March 30, 2025

     

    March 31, 2024

     

    % Change

     

    Currency

    Impact

     

    Constant

    Currency (a)

     

    Less: COVID-19

    revenue impact

     

    Constant Currency (a)

    ex COVID-19 Revenue

    North America

    $

    406.7

     

    $

    433.9

     

    (6.3)%

     

    0.2 %

     

    (6.5)%

     

    (5.9)%

     

    (0.6)%

    EMEA

     

    88.9

     

     

    84.8

     

    4.8 %

     

    (3.8)%

     

    8.6 %

     

    (0.3)%

     

    8.9 %

    China

     

    75.0

     

     

    76.1

     

    (1.4)%

     

    (1.3)%

     

    (0.1)%

     

    — %

     

    (0.1)%

    Other

     

    122.2

     

     

    116.2

     

    5.2 %

     

    (7.1)%

     

    12.3 %

     

    (0.7)%

     

    13.0 %

    Total revenues

    $

    692.8

     

    $

    711.0

     

    (2.6)%

     

    (1.5)%

     

    (1.1)%

     

    (4.0)%

     

    2.9 %

    (a)

    The term "constant currency" means we have translated local currency revenues for all reporting periods to U.S. dollars using currency exchange rates held constant for each period. This additional non-GAAP financial information is not meant to be considered in isolation from or as a substitute for financial information prepared in accordance with GAAP.

     

    QuidelOrtho

    Reconciliation of Non-GAAP Financial Information - Revenue excluding COVID-19 and Donor Screening

    (In millions, unaudited)

     

     

    Three Months Ended

     

     

     

     

     

     

     

    March 30, 2025

     

    March 31, 2024

     

    % Change

     

    Currency

    Impact

     

    Constant

    Currency (a)

    Total revenues

    $

    692.8

     

     

    $

    711.0

     

     

    (2.6)%

     

    (1.5)%

     

    (1.1)%

    COVID-19 revenue

     

    (23.4

    )

     

     

    (50.2

    )

     

     

     

     

     

     

    Donor Screening revenue

     

    (12.8

    )

     

     

    (33.3

    )

     

     

     

     

     

     

    Total revenue, excluding COVID-19 and Donor Screening

    $

    656.6

     

     

    $

    627.5

     

     

    4.6 %

     

    (1.8)%

     

    6.4 %

     

    QuidelOrtho

    Reconciliation of Non-GAAP Financial Information - Respiratory Revenue excluding COVID-19

    (In millions, unaudited)

     

     

    Three Months Ended

     

     

     

     

     

     

     

    March 30, 2025

     

    March 31, 2024

     

    % Change

     

    Currency

    Impact

     

    Constant

    Currency (a)

    Respiratory revenues

    $

    119.8

     

     

    $

    137.3

     

     

    (12.7)%

     

    (0.1)%

     

    (12.6)%

    COVID-19 revenue

     

    (23.4

    )

     

     

    (50.2

    )

     

     

     

     

     

     

    Total respiratory revenue, excluding COVID-19

    $

    96.4

     

     

    $

    87.1

     

     

    10.7 %

     

    (0.1)%

     

    10.8 %

    (a)

    The term "constant currency" means we have translated local currency revenues for all reporting periods to U.S. dollars using currency exchange rates held constant for each period. This additional non-GAAP financial information is not meant to be considered in isolation from or as a substitute for financial information prepared in accordance with GAAP.

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250507217806/en/

    Investor Contact:

    Juliet Cunningham

    Vice President, Investor Relations

    [email protected]

    Media Contact:

    D. Nikki Wheeler

    Senior Director, Corporate Communications

    [email protected]

    Get the next $QDEL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $QDEL

    DatePrice TargetRatingAnalyst
    5/8/2025$44.00Hold → Buy
    Jefferies
    12/11/2024$44.00 → $50.00Neutral → Buy
    Citigroup
    12/10/2024$43.00Hold
    Jefferies
    9/19/2024$42.00 → $50.00Neutral
    UBS
    9/5/2024$40.00 → $57.00Hold → Buy
    Craig Hallum
    3/4/2024$70.00 → $42.00Neutral → Sell
    UBS
    2/14/2024$66.00 → $37.00Neutral → Underweight
    JP Morgan
    12/11/2023$95.00 → $72.00Buy → Neutral
    Citigroup
    More analyst ratings

    $QDEL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • QuidelOrtho Reports First Quarter 2025 Financial Results

      ― Total revenue of $693 million, growth of 5% as reported and 6% in constant currency, excluding COVID-19 and Donor Screening ― ― Strong execution on cost-savings initiatives driving improved margins and profitability ― ― Company maintains full-year 2025 financial guidance ― First Quarter 2025 Results (all comparisons are to the prior year period) Total revenue was $693 million, as reported Non-respiratory revenue was $573 million, which was flat to the prior year period as reported and an increase of 2% in constant currency Labs revenue grew 5% as reported and 7% in constant currency Donor Screening revenue declined by 62% as the Company continues to wind down the U.S. portion of

      5/7/25 4:05:00 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • QuidelOrtho to Report First Quarter 2025 Financial Results

      QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company") or ("QuidelOrtho"), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it will report its financial results for its first quarter 2025 ended March 30, 2025, after the market close on Wednesday, May 7, 2025. Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results. Interested parties can access the call from the "Events & Presentations" section of the "Investor Relations" page of the Company's website at https://ir.quidelortho.c

      4/23/25 4:30:00 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • QuidelOrtho® Introduces Results Manager™ System

      Elevating laboratory efficiency and patient care QuidelOrtho Corporation (NASDAQ:QDEL) ("QuidelOrtho") announces the availability of the QuidelOrtho® Results Manager™ System, an informatics solution designed to address the growing demands of modern laboratories. The Results Manager system provides a seamless, user-friendly experience for community hospitals and point-of-care settings, strengthening informatics capabilities across QuidelOrtho's extensive diagnostics portfolio. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250310329666/en/QuidelOrtho® Results Manager™ System (Graphic: Business Wire) The QuidelOrtho Results Manage

      3/10/25 9:00:00 AM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $QDEL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Blaser Brian J. bought $249,878 worth of shares (6,033 units at $41.42) (SEC Form 4)

      4 - QuidelOrtho Corp (0001906324) (Issuer)

      12/13/24 4:12:57 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Busky Joseph M bought $99,663 worth of shares (2,150 units at $46.35) (SEC Form 4)

      4 - QuidelOrtho Corp (0001906324) (Issuer)

      2/26/24 6:48:23 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $QDEL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by QuidelOrtho Corporation

      SC 13G/A - QuidelOrtho Corp (0001906324) (Subject)

      12/6/24 10:11:24 AM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SC 13D/A filed by QuidelOrtho Corporation

      SC 13D/A - QuidelOrtho Corp (0001906324) (Subject)

      11/21/24 5:10:19 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SC 13G/A filed by QuidelOrtho Corporation

      SC 13G/A - QuidelOrtho Corp (0001906324) (Subject)

      11/14/24 1:28:35 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $QDEL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operations Officer Mclellan Philip D. was granted 1,945 shares and covered exercise/tax liability with 696 shares, increasing direct ownership by 14% to 10,237 units (SEC Form 4)

      4 - QuidelOrtho Corp (0001906324) (Issuer)

      4/29/25 4:09:19 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Chief Operations Officer Mclellan Philip D. covered exercise/tax liability with 1,159 shares and was granted 3,237 shares, increasing direct ownership by 30% to 8,988 units (SEC Form 4)

      4 - QuidelOrtho Corp (0001906324) (Issuer)

      4/24/25 4:03:44 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4 filed by Chief Legal Officer Hodges Michelle A

      4 - QuidelOrtho Corp (0001906324) (Issuer)

      4/22/25 4:03:40 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $QDEL
    SEC Filings

    See more
    • QuidelOrtho Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - QuidelOrtho Corp (0001906324) (Filer)

      5/7/25 4:07:42 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form DEFA14A filed by QuidelOrtho Corporation

      DEFA14A - QuidelOrtho Corp (0001906324) (Filer)

      4/8/25 4:06:30 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form DEF 14A filed by QuidelOrtho Corporation

      DEF 14A - QuidelOrtho Corp (0001906324) (Filer)

      4/8/25 4:05:50 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $QDEL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • QuidelOrtho upgraded by Jefferies with a new price target

      Jefferies upgraded QuidelOrtho from Hold to Buy and set a new price target of $44.00

      5/8/25 9:44:58 AM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • QuidelOrtho upgraded by Citigroup with a new price target

      Citigroup upgraded QuidelOrtho from Neutral to Buy and set a new price target of $50.00 from $44.00 previously

      12/11/24 8:21:07 AM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Jefferies initiated coverage on QuidelOrtho with a new price target

      Jefferies initiated coverage of QuidelOrtho with a rating of Hold and set a new price target of $43.00

      12/10/24 8:01:07 AM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $QDEL
    Financials

    Live finance-specific insights

    See more
    • QuidelOrtho Reports First Quarter 2025 Financial Results

      ― Total revenue of $693 million, growth of 5% as reported and 6% in constant currency, excluding COVID-19 and Donor Screening ― ― Strong execution on cost-savings initiatives driving improved margins and profitability ― ― Company maintains full-year 2025 financial guidance ― First Quarter 2025 Results (all comparisons are to the prior year period) Total revenue was $693 million, as reported Non-respiratory revenue was $573 million, which was flat to the prior year period as reported and an increase of 2% in constant currency Labs revenue grew 5% as reported and 7% in constant currency Donor Screening revenue declined by 62% as the Company continues to wind down the U.S. portion of

      5/7/25 4:05:00 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • QuidelOrtho to Report First Quarter 2025 Financial Results

      QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company") or ("QuidelOrtho"), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it will report its financial results for its first quarter 2025 ended March 30, 2025, after the market close on Wednesday, May 7, 2025. Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results. Interested parties can access the call from the "Events & Presentations" section of the "Investor Relations" page of the Company's website at https://ir.quidelortho.c

      4/23/25 4:30:00 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • QuidelOrtho Reports Fourth Quarter and Full-Year 2024 Financial Results

      Strong finish to 2024 with continued progress in cost-savings initiatives to drive adjusted EBITDA margin expansion in 2025 and beyond Company issues full-year 2025 financial guidance Fourth Quarter and Full-Year 2024 Results (all comparisons are to the prior year period) Fourth quarter 2024 revenue was $708 million, as reported Non-respiratory revenue was $565 million, which was flat compared to the prior year period due to a decline in U.S. Donor Screening revenue, a business the Company is exiting; Labs revenue grew 4%, as reported and in constant currency, excluding COVID-19 and non-core revenues1 Respiratory revenue was $143 million, a decrease of 18%, as reported and in co

      2/12/25 4:05:00 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $QDEL
    Leadership Updates

    Live Leadership Updates

    See more
    • QuidelOrtho Announces Appointment of Two Independent Directors to its Board

      Veteran Healthcare CEOs John R. Chiminski and R. Scott Huennekens Bring Deep Industry Experience, Operational Expertise and Financial Acumen to the QuidelOrtho Board QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the "Board"), effective December 6, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210769572/en/R. Scott Huennekens (Photo: Business Wire) T

      12/10/24 7:00:00 AM ET
      $CTLT
      $HYPR
      $NVST
      $QDEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Medical/Dental Instruments
    • QuidelOrtho Announces New R&D Executive Leader

      Jonathan Siegrist appointed as EVP of R&D and CTO QuidelOrtho Corporation (NASDAQ:QDEL), a global leader in innovative diagnostic solutions, is pleased to announce the appointment of Jonathan Siegrist, PhD, as its new Executive Vice President of Research and Development (R&D) and Chief Technology Officer (CTO), effective as of October 7, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241009251239/en/Jonathan Siegrist, EVP of R&D and CTO, QuidelOrtho (Photo: Business Wire) Siegrist brings a wealth of industry expertise and leadership experience with over 15 years in molecular diagnostics, microfluidic platforms, and biomedi

      10/9/24 7:00:00 AM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • QuidelOrtho Appoints Lee Bowman as Chief Human Resources Officer

      QuidelOrtho Corporation (NASDAQ:QDEL) is pleased to announce the appointment of Lee Bowman as Chief Human Resources Officer (CHRO). In this pivotal role, Bowman leads QuidelOrtho's human resources strategy, driving initiatives that bolster a dynamic and inclusive workplace culture. Bowman reports to Brian Blaser, President and Chief Executive Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240910545042/en/Lee Bowman, Chief Human Resources Officer, QuidelOrtho (Photo: Business Wire) Bowman brings over 25 years of experience in human resources leadership, with a distinguished career that spans key roles in major industries.

      9/10/24 7:00:00 AM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care